Press Releases

CAMBRIDGE, Mass. , Oct. 31, 2018 /PRNewswire/ --   Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its third quarter 2018 investor conference call and webcast at 8:30 am ET on Wednesday, November 7, 2018.   The call will provide an update on Merrimack's

- MM-121 did not improve progression free survival (PFS) in patients with non-small cell lung cancer (NSCLC) - - Company to provide pipeline review update on third quarter financial results call, November 7, 2018 - CAMBRIDGE, Mass. , Oct. 19, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. 

CAMBRIDGE, Mass. , Sept. 20, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first

CAMBRIDGE, Mass. , Sept. 6, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead

- $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources - - Two clinical readouts anticipated in 2018: randomized Phase 2 SHERLOC study of MM-121 in metastatic non-small cell lung cancer and Phase 1 study of MM-310 in solid tumors

CAMBRIDGE, Mass. , July 31, 2018 /PRNewswire/ --   Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its second quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, August 7, 2018.   The call will provide an update on Merrimack's recent

- Non-dilutive financing strengthens cash position - - Multiple clinical read-outs expected later this year - CAMBRIDGE, Mass. , July 2, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the

- CARRIE study did not meet primary or secondary endpoints - - Company ceases development of MM-141 - - Focus remains on advancing Merrimack's promising clinical and preclinical pipeline, with two additional clinical study readouts anticipated in 2H 2018 - CAMBRIDGE, Mass.

CAMBRIDGE, Mass. , May 29, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it will present two posters at the American Society of Clinical Oncology ( ASCO ) Annual Meeting, June 1-5,

- Three clinical readouts expected in 2018, including data from two randomized Phase 2 studies - - Conference call at 8:30 am ET today - CAMBRIDGE, Mass. , May 8, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined